On Invalid Date, Cardiol Therapeutics (NASDAQ: CRDL) reported Q1 2023 earnings per share (EPS) of -$0.08, up 27.93% year over year. Total Cardiol Therapeutics earnings for the quarter were -$5.14 million. In the same quarter last year, Cardiol Therapeutics's earnings per share (EPS) was -$0.11.
As of Q2 2023, Cardiol Therapeutics's earnings has grown year over year. Cardiol Therapeutics's earnings in the past year totalled -$21.37 million.
What was CRDL's revenue last quarter?
On Invalid Date, Cardiol Therapeutics (NASDAQ: CRDL) reported Q1 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Cardiol Therapeutics's revenue was $0.00.
What was CRDL's revenue growth in the past year?
As of Q2 2023, Cardiol Therapeutics's revenue has grown -100% year over year. This is 106.48 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 6.48%. Cardiol Therapeutics's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.